The Role of P4HB and SOX4 in Prostatic Carcinoma and Their Clinical Significance

  • 0Department of Pathology, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt.

|

|

Summary

This summary is machine-generated.

New biomarkers P4HB and SOX4 show promise for diagnosing prostate cancer (prostatic adenocarcinoma). These proteins are highly expressed in tumors and correlate with aggressive features, aiding in prognosis.

Area Of Science

  • Oncology
  • Pathology
  • Biomarker Discovery

Background

  • Prostatic adenocarcinoma (PAC) is a leading cause of cancer death in men.
  • Accurate diagnosis of PAC can be challenging, necessitating novel immunohistochemical markers.
  • Identifying new biomarkers is crucial for improving diagnostic reliability and patient outcomes.

Purpose Of The Study

  • To investigate the expression of P4HB and SOX4 in prostatic carcinoma.
  • To explore the potential roles and clinical significance of P4HB and SOX4 as biomarkers.
  • To compare the expression of P4HB and SOX4 between PAC and benign prostatic hyperplasia (NPH).

Main Methods

  • Retrospective analysis of 56 PAC and 56 NPH cases.
  • Immunohistochemical staining for P4HB and SOX4.
  • Correlation of protein expression with clinicopathological parameters, including Gleason score and invasion patterns.

Main Results

  • P4HB and SOX4 showed significantly higher expression in PAC compared to NPH (P<0.001).
  • SOX4 demonstrated high diagnostic accuracy (89% sensitivity, 100% specificity, AUC=0.946).
  • Both markers correlated with Gleason score, and SOX4 showed an inverse relation with ERG expression.

Conclusions

  • P4HB and SOX4 possess significant diagnostic and prognostic value in prostatic adenocarcinoma.
  • Their expression is linked to tumor aggressiveness and invasion, suggesting a role in disease progression.
  • SOX4 and P4HB may serve as valuable adjuncts in the pathological assessment of PAC.